Asad Haider
Stock Analyst at Goldman Sachs
(2.79)
# 1,961
Out of 5,090 analysts
13
Total ratings
80%
Success rate
17.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $35.26 | +4.93% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $52.15 | +9.30% | 2 | Dec 2, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $186 → $212 | $201.93 | +4.99% | 2 | Oct 9, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $20.74 | -18.03% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $39.73 | +5.71% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $46.48 | -18.24% | 1 | Sep 12, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $96.25 | +14.29% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,010.31 | -12.11% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $226.08 | -14.19% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $26.03 | -3.96% | 1 | Apr 8, 2025 |
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $35.26
Upside: +4.93%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $52.15
Upside: +9.30%
Johnson & Johnson
Oct 9, 2025
Maintains: Buy
Price Target: $186 → $212
Current: $201.93
Upside: +4.99%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $20.74
Upside: -18.03%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $39.73
Upside: +5.71%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $46.48
Upside: -18.24%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $96.25
Upside: +14.29%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,010.31
Upside: -12.11%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $226.08
Upside: -14.19%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $26.03
Upside: -3.96%